Roche: combo treatment meets goals in leukaemia trial

(CercleFinance.com) - Roche said on Monday that a combination treatment of its Venclexta/Venclyxto drug in combination with azacitidine met the main goals of a late-stage study in patients with previously untreated acute myeloid leukaemia.


The combination resulted in a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone, the Swiss drugmaker said.

The Phase III trial also met its endpoint when it came to composite complete remission rate, it said.

The Venclexta/Venclyxto medicine has been designed to bind and inhibit the B-cell lymphoma-2 protein, which prevents cancer cells from dying or self-destructing in some blood cancers.

Copyright (c) 2020 CercleFinance.com. All rights reserved.